Where Will Iovance Biotherapeutics Be in 5 Years?
Iovance Biotherapeutics (NASDAQ: IOVA), a small-cap biotech company, has an innovative approach to treating cancer that ...
ETF Daily News5d
Iovance Biotherapeutics (NASDAQ:IOVA) Reaches New 1-Year Low on Analyst Downgrade
Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic ...
Business Insider26d
Iovance Biotherapeutics (IOVA) Gets a Buy from Truist Financial
Truist Financial analyst Asthika Goonewardene maintained a Buy rating on Iovance Biotherapeutics (IOVA ... is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes ...
Yahoo Finance23d
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Jan. 17, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics ... system’s ability to recognize and destroy diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising ...
AOL10d
What's Wrong With Iovance Biotherapeutics Stock?
It was about a year ago that shares of Iovance Biotherapeutics (NASDAQ: IOVA) began to take off. The stock soared on news of approval from the Food and Drug Administration for Amtagvi (lifileucel ...
Yahoo Finance11d
Where Will Iovance Biotherapeutics Be in 5 Years?
Iovance Biotherapeutics (NASDAQ ... The company seeks to develop therapies that enhance patients' cancer-fighting cells, specifically tumor-infiltrating lymphocytes (TILs). Iovance collects ...